Healthcare / BiotechnologyTSXV
$0.06
-0.00 (-8.33%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 23%
FCF escenarios
weak_data · normalized FCF $-3.2M · quality 65.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
18/100
F
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$39M
P/E
N/A
•EV/EBITDA
N/A
•ROE
20.1%
↑Gross Margin
71.9%
↑Debt/Equity
-0.47
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-36.8%
FCF CAGR
—
FCF margin
-1310.9%
FCF / Net income
0.70x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $240509.0 · net income $-4.5M · FCF $-3.2M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $240509.00 | $240509.00 | $412568.00 | $432529.00 | $952127.00 |
| Net Income | $-4.5M | $-4.5M | $-3.3M | $-2.7M | $-1.8M |
| EBITDA | $-3.1M | $-3.1M | $-2.1M | $-1.6M | $-1.1M |
| EPS | -0.01 | -0.01 | -0.01 | -0.00 | -0.00 |
| Gross Margin | 71.9% | 71.9% | 54.9% | 69.4% | 31.9% |
| Operating Margin | -1434.0% | -1434.0% | -589.0% | -411.1% | -133.3% |
| Net Margin | -1881.2% | -1881.2% | -806.2% | -618.6% | -192.4% |
| Balance Sheet | |||||
| Debt/Equity | -0.47 | -0.47 | -0.53 | -0.62 | -0.67 |
| Current Ratio | 0.07 | 0.07 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-3.2M | $-3.2M | $-3.7M | $-1.3M | $-2.0M |
| Returns | |||||
| ROE | 20.1% | 20.1% | 18.4% | 17.8% | 14.8% |
| Growth & Yield | |||||
| Revenue Growth | -41.7% | -41.7% | -4.6% | -54.6% | — |
| EPS Growth | -20.0% | -20.0% | -25.0% | -33.3% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-38.9%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.01 → -0.01
Residual
-38.9%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.